The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: A retrospective, single-centre study

European Journal of Pediatrics

Volumn 170, Issue 7, 2011, Pages 907-913

  Butt, Michelle L ^a   Symington, Amanda ^b   Janes, Marianne ^b   Elliott, LouAnn ^b   Steele, Susan ^a   Paes, Bosco A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER CHILDREN S HOSPITAL   (Canada)

Author keywords

Admissions; PICU; Prophylaxis; RSV

Indexed keywords

PALIVIZUMAB;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD MORTALITY; COMORBIDITY; FEMALE; GROUPS BY AGE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SCHOOL CHILD;

ADOLESCENT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, PEDIATRIC; MALE; ONTARIO; PATIENT ADMISSION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 79959764288     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-010-1376-3     Document Type: Article

References (53)

1. Abman SH, Ogle JW, Butler-Simon N et al (1988) Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113:826-830
2. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis (2006) Diagnosis and management of bronchiolitis. Pediatrics 118:1774-1793
3. Arnold SR, Wang EE, Law BJ et al (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 18:866-869 (Pubitemid 29487505)
4. Banerji A, Bell A, Mills EL et al (2001) Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 164:1847-1850 (Pubitemid 32702069)
5. Banerji A, Greenberg D, White LF et al (2009) Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: a case-control study. Pediatr Infect Dis J 28:697-701
6. Berger TM, Aebi C, Duppenthaler A, Swiss Pediatric Surveillance Unit et al (2009) Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005). Infection 37:109-116
7. Bloemers BL, van Furth AM, Weijerman ME et al (2007) Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 120: e1076-e1081 (Pubitemid 47549555)
8. Committee on Infectious Diseases, From the American Academy of Pediatrics (2009) Policy statements, modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124:1694-1701
9. Crowcroft NS, Zambon M, Harrison TG et al (2008) Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families. Eur J Pediatr 167:395-399 (Pubitemid 351322469)
10. Duttweiler L, Nadal D, Frey B (2004) Pulmonary and systemic bacterial co-infections in severe RSV bronchiolitis. Arch Dis Child 89:1155-1157
11. Feltes TF, Cabalka AK, Meissner HC, Cardiac Synagis Study Group et al (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532-540 (Pubitemid 37352516)
12. Figueras-Aloy J, Carbonell Estrany X, Comité de Estándares de la Sociedad Española de Neonatología (2010) Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation). An Paediatr (Barc) 73:98.e1-4
13. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group (2004) Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 23:815-820 (Pubitemid 40221022)
14. Frogel M, Nerwen C, Cohen A, Palivizumab Outcomes Registry Group et al (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 28:511-517 (Pubitemid 351973995)
15. Hall CB, Weinberg GA, Iwane MK et al (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588-598
16. Horn SD, Smout RJ (2003) Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 143: S133-S141 (Pubitemid 37456911)
17. Kristensen K, Stensballe LG, Bjerre J et al (2009) Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 94:785-789
18. Law BJ, Langley JM, Allen U et al (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 23:806-814 (Pubitemid 40221021)
19. Law BJ, MacDonald N, Langley J et al (1998) Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent? Paediatr Child Health 3:402-404
20. Leader S, Kohlase K (2003) Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 143:S127-S132 (Pubitemid 37456910)
21. Levin D, Tribuzio M, Green-Wrzesinki T, Ames B et al (2010) Empiric antibiotics are justified for infants with respiratory syncytial virus lower respiratory tract infection presenting with respiratory failure: a prospective study and evidence review. Pediatr Crit Care Med 11:390-395
22. López Guinea A, Casado Flores J, Martín Sobrino MA et al (2007) Severe bronchiolitis. Epidemiology and clinical course of 284 patients. An Pediatr (Barc) 67:116-122
23. McLaurin KK, Leader S (2005) Growing impact of RSV hospitalizations among infants in the US, 1997-2002. Abstract 936. Presented at: Pediatric Academic Societies Annual Meeting, May 14-17, Washington, USA
24. Meert K, Heidemann S, Abella B et al (1990) Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 18:1357-1359
25. Mori M, Kawashima H, Nakamura H et al, Surveillance Committee for Severe RSV Infection (2010) Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother (in press)
26. Nair H, Nokes DJ, Gessner BD et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555
27. Oh PI, Lanctot KL, Yoon A, Composs Investigators et al (2002) Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 21:512-518 (Pubitemid 34625831)
28. Paes B, Li A, Lanctot KL et al (2010) CARESS: the Canadian Registry of Synagis (2006-2009). Abstract 753409. Presented at: Pediatric Academic Societies Annual Meeting, May 1st-4th, Vancouver, Canada
29. Paes B, Steele S, Janes M et al (2009) Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 25:1585-1591
30. Paes B, Cole M, Latchman A et al (2009) Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Curr Med Res Opin 25:2191-2196
31. Paes B, Mitchell I, Li A et al (2010) Respiratory syncytial virus prophylaxis in special populations. Abstract 754319. Presented at: Pediatric Academic Societies Annual Meeting, May 1st-4th, Vancouver, Canada
32. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, IRIS Study Group et al (2003) Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22:823-827 (Pubitemid 37153079)
33. Prais D, Schonfeld T, Amir J, Israeli Respiratory Syncytial Virus Monitoring Group (2003) Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics 112:548-552 (Pubitemid 37082105)
34. Purcell K, Fergie J (2004) Driscoll children's hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J 23:418-423
35. Ralston S, Hill V (2009) Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr 155:728-733
36. Randolph AG, Reder L, Englund JA (2004) Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit. Pediatr Infect Dis J 23:990-994 (Pubitemid 40824286)
37. Resch B, Gusenleitner W, Müller W (2002) The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 30:193-197
38. Resch B, Berger A, Bernert G et al (2008) Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung. Monatsschr Kinderheilkd 156:381-383
39. Resch B, Gusenleitner W, Müller WD et al (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis 25:120-122 (Pubitemid 43333675)
40. Resch B, Gusenleitner W, Mueller WD (2007) Risk of concurrent bacterial infection in preterm infants hospitalized due to respiratory syncytial virus infection. Acta Paediatr 96:495-498 (Pubitemid 46466123)
41. Sampalis JS, Langley J, Carbonell-Estrany X et al (2008) Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Mak 28:471-480 (Pubitemid 351989998)
42. Samson L (2009) The Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Paediatr Child Health 14:521-526
43. Schanzer DL, Langley JM, Tam TW (2006) Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 25:795-800 (Pubitemid 44334824)
44. Simões EA, Carbonell-Estrany X, Fullarton JR, European RSV Risk Factor Study Group et al (2008) A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res 9:78
45. Simoes EA (2003) Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 143:S118-S126
46. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537
47. Thibeault R, Gilca R, Cote S, De Serres G et al (2007) Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus. J Clin Virol 39:169-174 (Pubitemid 46924796)
48. Thorburn K (2009) Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 94:99-103
49. Thorburn K, Harigopal S, Reddy Vet al (2006) High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax 61:611-615 (Pubitemid 44035142)
50. Thorburn K, Van Saene H (2007) Pulmonary bacterial coinfection in children ventilated for severe respiratory syncytial virus bronchiolitis is common. Intensive Care Med 33:565 (Pubitemid 46333829)
51. Wang EE, Law BJ, Stephens D (1995) Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 126:212-219
52. Welliver RC (2003) Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 143:S112-S117
53. Wilkesmann A, Ammann RA, Schildgen O, DSM RSV Ped Study Group et al (2007) Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 26:485-491 (Pubitemid 46847308)